TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06748040

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic (PGx) testing
Description: Participants will be randomized to immediate versus delayed return of PGx results.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic (PGx) testing
Description: Participants will be randomized to immediate versus delayed return of PGx results.
Study: NCT03084523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol Injectable Product
Description: Patients will be administered a single dose of ferumoxytol as an MRI contrast
Study: NCT00527826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
Description: comparator
Study: NCT01222000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
Description: After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
Description: After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
Study: NCT01144455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar (Gemcitabine)
Description: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar (Gemcitabine)
Description: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Study: NCT06763510

Intervention type: DRUG
Intervention: Chirocaine
Description: Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Isobaric levobupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.

Intervention type: DRUG
Intervention: Bupivacaine
Description: Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Hyperbaric bupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
Study: NCT04225442

Intervention type: OTHER
Group type: OTHER
Intervention: Fatty meal to challenge the physiological chronobiome in healthy young and old
Description: The intervention consists of a fatty meal
Study: NCT00109174

Intervention type: DEVICE
Group type: OTHER
Intervention: 3T and 7T device
Description: 3T and 7T device
Study: NCT03255746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Enhancement
Description: This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
Study: NCT04193189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENGERIX-B
Description: Administered by IM injection
Study: NCT02259855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT04216576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Drug Diary
Description: Participants will receive and use a paper Drug Diary and a paper medication calendar.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OhMD APP
Description: Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
Study: NCT02872532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular tissue cryopreservation
Description: Testicular tissue will be removed
Study: NCT03899792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-292
Description: Oral LOXO-292
Study: NCT00682318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Safflower Oil
Description: Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-6 polyunsaturated fatty acid
Description: Part 2b:~Control omega-6 fatty acid alimentary diet (\<130 mg/day EPA/DHA)
Study: NCT02678455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV005 vaccine
Description: Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered by subcutaneous injection
Study: NCT04445337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: An injection of local anesthetic into the front of the neck. SGB involves placing a small tube into the front of your neck, toward nerves at the back of your neck. This is done with the help of an x-ray machine or ultrasound device. The tube is left in place so you can get medication thru it for five days. Then the tube is taken out.~The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block. These medications are approved by the Food and Drug Administration (FDA).
Study: NCT03572881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial mapping
Description: An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial mapping
Description: An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.
Study: NCT01976247

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Focused Ultrasound Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Cryolipolysis Device
Study: NCT04161651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eversense
Description: eversense CGM
Study: NCT04239599

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT Radiation treatment

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated IMRT Radiation treatment
Study: NCT02895919

Intervention type: OTHER
Intervention: Culture
Description: culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).

Intervention type: OTHER
Intervention: Culture
Description: culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
Study: NCT04647747

Intervention type: OTHER
Group type: OTHER
Intervention: Self measurement with pulse oximeter
Description: Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
Study: NCT03192462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multiTAA specific T cells
Description: Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multiTAA specific T cells
Description: Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multiTAA specific T cells
Description: Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
Study: NCT03816761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart
Description: In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart
Description: In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet™
Description: The bionic pancreas including pigtail adapters, used in insulin-only configuration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet™
Description: The bionic pancreas including pigtail adapters, used in insulin-only configuration
Study: NCT01030393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotrophin
Description: intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
Study: NCT02859077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: EGFR-TKI (gefitinib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy（pemetrexed/gemcitabine）
Description: Chemotherapy (pemetrexed/gemcitabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy（carboplatin）
Description: Chemotherapy（carboplatin）
Study: NCT01174069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOTES assisted laparoscopic cholecystectomy
Description: Surgical removal of the gallbladder using endoscopic instruments.
Study: NCT04358432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies
Study: NCT01255254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival scaling
Description: Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
Study: NCT03455998

Intervention type: OTHER
Intervention: questionnaires

Intervention type: OTHER
Intervention: questionnaires
Study: NCT01817322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose of Myfortic and Reduced Dose of Myfortic
Description: Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose of Myfortic and Reduced Dose of Myfortic
Description: Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
Description: 500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
Description: 500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab injected both control group and experimental group
Description: The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab injected both control group and experimental group
Description: The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
Study: NCT02857075

Intervention type: OTHER
Intervention: Blood donation
Description: Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.

Intervention type: OTHER
Intervention: Blood donation
Description: Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
Study: NCT03325790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg SPI-1005 BID
Description: Active: low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg SPI-1005 BID
Description: Active: high dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02080962

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30 Gy in 5 fractions
Description: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 40 Gy in 10 fractions
Description: tumors \> 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
Study: NCT01682551

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Medicine
Description: The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Medicine
Description: The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day.
Study: NCT01144455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemzar (Gemcitabine)
Description: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Study: NCT01682551

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetalozamide
Description: If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang.
Study: NCT02666664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Study: NCT03880253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Placebo or CTP-692
Study: NCT01144455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Study: NCT02131064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion at a dose to achieve an AUC of 6 mg\*min/mL q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV infusion q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w